As an example, preclinical studies of acquired resistance to trastuzumab–maytansinoid ADC showed that primary mediators of resistance upon chronic tumor cell treatment with T-DM1 were increased ABCC1 protein and reduced HER2 antigen expression [17]. This evidence concerns the gene ERBB2 and neoplasm.